ZA200307803B - Erythropoietin ameliorates chemotherapy-induced toxicity in vivo. - Google Patents

Erythropoietin ameliorates chemotherapy-induced toxicity in vivo. Download PDF

Info

Publication number: ZA200307803B
Authority: ZA; South Africa
Prior art keywords: erythropoietin; toxicity; administered; agent; epo
Prior art date: 2001-04-09

Application number

ZA200307803A

Other languages

English (en)

Inventor

George Signounas

Paul Mehlhop

Original Assignee

Univ East Carolina

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-09

Filing date

2003-10-06

Publication date

2005-02-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23082337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200307803(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-10-06 Application filed by Univ East Carolina filed Critical Univ East Carolina

2005-02-09 Publication of ZA200307803B publication Critical patent/ZA200307803B/en

Links

108090000394 Erythropoietin Proteins 0.000 title claims description 50
102000003951 Erythropoietin Human genes 0.000 title claims description 49
229940105423 erythropoietin Drugs 0.000 title claims description 48
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims description 46
238000002512 chemotherapy Methods 0.000 title claims description 8
230000001988 toxicity Effects 0.000 title claims description 8
231100000419 toxicity Toxicity 0.000 title claims description 8
238000001727 in vivo Methods 0.000 title 1
238000000034 method Methods 0.000 claims description 38
239000002246 antineoplastic agent Substances 0.000 claims description 30
229940127089 cytotoxic agent Drugs 0.000 claims description 27
229940034982 antineoplastic agent Drugs 0.000 claims description 16
239000002254 cytotoxic agent Substances 0.000 claims description 16
231100000599 cytotoxic agent Toxicity 0.000 claims description 16
108010006654 Bleomycin Proteins 0.000 claims description 13
229960001561 bleomycin Drugs 0.000 claims description 13
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical group N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 13
206010061924 Pulmonary toxicity Diseases 0.000 claims description 7
231100000374 pneumotoxicity Toxicity 0.000 claims description 7
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
229940122803 Vinca alkaloid Drugs 0.000 claims description 6
230000007047 pulmonary toxicity Effects 0.000 claims description 6
230000000699 topical effect Effects 0.000 claims description 6
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 5
210000004072 lung Anatomy 0.000 claims description 5
229960004857 mitomycin Drugs 0.000 claims description 5
229930192392 Mitomycin Natural products 0.000 claims description 4
102000015696 Interleukins Human genes 0.000 claims description 3
108010063738 Interleukins Proteins 0.000 claims description 3
150000008052 alkyl sulfonates Chemical class 0.000 claims description 3
239000003242 anti bacterial agent Substances 0.000 claims description 3
230000003115 biocidal effect Effects 0.000 claims description 3
229960005243 carmustine Drugs 0.000 claims description 3
150000002224 folic acids Chemical class 0.000 claims description 3
231100000433 cytotoxic Toxicity 0.000 claims description 2
230000001472 cytotoxic effect Effects 0.000 claims description 2
OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 2
206010029350 Neurotoxicity Diseases 0.000 claims 1
231100000153 central nervous system (CNS) toxicity Toxicity 0.000 claims 1
231100000304 hepatotoxicity Toxicity 0.000 claims 1
230000007056 liver toxicity Effects 0.000 claims 1
231100000417 nephrotoxicity Toxicity 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 24
239000000203 mixture Substances 0.000 description 15
108090000765 processed proteins & peptides Proteins 0.000 description 12
238000009472 formulation Methods 0.000 description 11
238000011282 treatment Methods 0.000 description 11
241001465754 Metazoa Species 0.000 description 8
230000009325 pulmonary function Effects 0.000 description 8
102000004196 processed proteins & peptides Human genes 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
108010074604 Epoetin Alfa Proteins 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000007788 liquid Substances 0.000 description 6
101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 4
101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 4
208000007502 anemia Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000008187 granular material Substances 0.000 description 4
102000044890 human EPO Human genes 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
230000003278 mimic effect Effects 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
108010092160 Dactinomycin Proteins 0.000 description 3
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000003817 anthracycline antibiotic agent Substances 0.000 description 3
230000000118 anti-neoplastic effect Effects 0.000 description 3
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
229940044683 chemotherapy drug Drugs 0.000 description 3
229960000640 dactinomycin Drugs 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000000813 microbial effect Effects 0.000 description 3
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 3
229960003171 plicamycin Drugs 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
231100000155 toxicity by organ Toxicity 0.000 description 3
230000007675 toxicity by organ Effects 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 2
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
108010075944 Erythropoietin Receptors Proteins 0.000 description 2
102100036509 Erythropoietin receptor Human genes 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
229960002092 busulfan Drugs 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
229960003388 epoetin alfa Drugs 0.000 description 2
229940089118 epogen Drugs 0.000 description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
229960005420 etoposide Drugs 0.000 description 2
239000012634 fragment Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 2
229960002329 methacholine Drugs 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
238000000465 moulding Methods 0.000 description 2
210000005170 neoplastic cell Anatomy 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
229940029359 procrit Drugs 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
208000005069 pulmonary fibrosis Diseases 0.000 description 2
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
229960003440 semustine Drugs 0.000 description 2
239000007787 solid Substances 0.000 description 2
YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical compound O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 1
AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
208000037157 Azotemia Diseases 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
102100021906 Cyclin-O Human genes 0.000 description 1
MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
108010026389 Gramicidin Proteins 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
229930126263 Maytansine Natural products 0.000 description 1
241000750002 Nestor Species 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
206010036590 Premature baby Diseases 0.000 description 1
AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229960001220 amsacrine Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
229940108502 bicnu Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
-1 cachets Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
208000019069 chronic childhood arthritis Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
238000009510 drug design Methods 0.000 description 1
AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
229960002694 emetine Drugs 0.000 description 1
AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
230000009422 growth inhibiting effect Effects 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
229940003183 hexalen Drugs 0.000 description 1
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000003434 inspiratory effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
229940090009 myleran Drugs 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229940063179 platinol Drugs 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000008817 pulmonary damage Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
229950010131 puromycin Drugs 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
239000000176 sodium gluconate Substances 0.000 description 1
235000012207 sodium gluconate Nutrition 0.000 description 1
229940005574 sodium gluconate Drugs 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000008719 thickening Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
208000009852 uremia Diseases 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000002023 wood Substances 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

ZA200307803A 2001-04-09 2003-10-06 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo. ZA200307803B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US28262101P	2001-04-09	2001-04-09

Publications (1)

Publication Number	Publication Date
ZA200307803B true ZA200307803B (en)	2005-02-09

Family

ID=23082337

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200307803A ZA200307803B (en)	2001-04-09	2003-10-06	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo.

Country Status (22)

Country	Link
US (2)	US20020169128A1 (pt)
EP (1)	EP1377164B1 (pt)
JP (1)	JP4428924B2 (pt)
KR (1)	KR100885525B1 (pt)
CN (2)	CN101152565A (pt)
AT (1)	ATE399020T1 (pt)
AU (1)	AU2002256133B2 (pt)
BR (1)	BR0208727A (pt)
CA (1)	CA2443025A1 (pt)
DE (1)	DE60227244D1 (pt)
DK (1)	DK1377164T3 (pt)
ES (1)	ES2309166T3 (pt)
HU (1)	HUP0303838A3 (pt)
IL (3)	IL158155A0 (pt)
MX (1)	MXPA03009182A (pt)
NO (1)	NO20034504L (pt)
NZ (1)	NZ528675A (pt)
PL (1)	PL373361A1 (pt)
PT (1)	PT1377164E (pt)
RU (1)	RU2296563C2 (pt)
WO (1)	WO2002080676A1 (pt)
ZA (1)	ZA200307803B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP2067488A1 (en)	2000-04-12	2009-06-10	Human Genome Sciences, Inc.	Albumin fusion proteins
CA2471363C (en)	2001-12-21	2014-02-11	Human Genome Sciences, Inc.	Albumin fusion proteins
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
CA2525464A1 (en) *	2003-05-12	2004-11-25	Qun Yin	Novel poly(ethylene glycol) modified compounds and uses thereof
BRPI0411172A (pt) *	2003-05-12	2006-07-18	Affymax Inc	peptìdeo, dìmero de peptìdeo, seu uso e composição farmacêutica
CA2525568C (en) *	2003-05-12	2017-07-25	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
EA010015B1 (ru)	2003-05-12	2008-06-30	Афимакс, Инк.	Новый разделительный фрагмент (спейсер) для модифицированных полиэтиленгликолем соединений на основе пептидов
US20080312201A1 (en) *	2004-09-10	2008-12-18	Patrick Fogarty	Reduced Toxicity Methotrexate Formulations and Methods for Using the Same
WO2006062685A2 (en) *	2004-11-11	2006-06-15	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
MX2007005777A (es) *	2004-11-11	2007-07-20	Affymax Inc	Peptidos novedosos que se unen al receptor de eritropoietina.
US8324159B2 (en) *	2005-06-03	2012-12-04	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) *	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7919461B2 (en)	2005-06-03	2011-04-05	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
JPWO2008023725A1 (ja) *	2006-08-22	2010-01-14	中外製薬株式会社	末梢神経障害の予防および／または治療剤
US20080249001A1 (en) *	2006-10-25	2008-10-09	Ajinomoto Co. Inc.	Agents that alleviate side-effects caused by chemotherapy agents
EP1992355A1 (en) *	2007-05-16	2008-11-19	Eberhardt Spanuth	Pharmaceutical combination medication comprising NSAIDs or cytoxic drugs
RU2410095C2 (ru) *	2009-04-20	2011-01-27	Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева"	Средство для повышения эффективности и снижения токсичности противоопухолевых препаратов
EP4026563A1 (en) *	2015-06-18	2022-07-13	Yeda Research and Development Co. Ltd	Conditioning protocols and use of same for tissue regeneration
US10695402B2 (en)	2017-03-16	2020-06-30	University Of Rochester	Erythropoietin for gastrointestinal dysfunction
WO2022159414A1 (en)	2021-01-22	2022-07-28	University Of Rochester	Erythropoietin for gastroinfestinal dysfunction

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4859765A (en) *	1983-10-17	1989-08-22	Syntex (U.S.A.) Inc.	Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US4863857A (en) *	1985-03-01	1989-09-05	Board Of Regents, The University Of Texas System	Polypeptide complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known
NZ215865A (en) *	1985-04-22	1988-10-28	Commw Serum Lab Commission	Method of determining the active site of a receptor-binding analogue
IT210425Z2 (it) *	1987-01-22	1988-12-30	Erga Srl	Portachiavi con mezzo di scrittura telescopico incorporato
US4853871A (en) *	1987-04-06	1989-08-01	Genex Corporation	Computer-based method for designing stablized proteins
US4856871A (en) *	1987-08-31	1989-08-15	General Electric Company	Replaceable laser and lens assembly
JP2632014B2 (ja) *	1988-03-03	1997-07-16	中外製薬株式会社	骨髄機能障害性貧血治療剤
GB9613070D0 (en) *	1996-06-21	1996-08-28	Rowett Research Services Limit	Dietary lectins
US20020052309A1 (en) *	1996-09-11	2002-05-02	Athanasius A. Anagnostou	Method of treating endothelial injury
US6719977B1 (en) *	1998-02-12	2004-04-13	The General Hospital Corporation	Methods to potentiate cancer therapies
RU2248215C2 (ru) *	1999-05-11	2005-03-20	Орто-Макнейл Фармасьютикал, Инк.	Фармакокинетическое и фармакодинамическое моделирование введения эритропоэтина
US6531121B2 (en) *	2000-12-29	2003-03-11	The Kenneth S. Warren Institute, Inc.	Protection and enhancement of erythropoietin-responsive cells, tissues and organs

2002
- 2002-04-05 US US10/117,011 patent/US20020169128A1/en not_active Abandoned
- 2002-04-08 KR KR1020037013132A patent/KR100885525B1/ko not_active Expired - Fee Related
- 2002-04-08 NZ NZ528675A patent/NZ528675A/en unknown
- 2002-04-08 DK DK02725577T patent/DK1377164T3/da active
- 2002-04-08 EP EP02725577A patent/EP1377164B1/en not_active Revoked
- 2002-04-08 CN CNA2007101533855A patent/CN101152565A/zh active Pending
- 2002-04-08 PL PL02373361A patent/PL373361A1/xx not_active Application Discontinuation
- 2002-04-08 MX MXPA03009182A patent/MXPA03009182A/es active IP Right Grant
- 2002-04-08 AT AT02725577T patent/ATE399020T1/de not_active IP Right Cessation
- 2002-04-08 CN CNB028078136A patent/CN100379446C/zh not_active Expired - Fee Related
- 2002-04-08 DE DE60227244T patent/DE60227244D1/de not_active Expired - Lifetime
- 2002-04-08 PT PT02725577T patent/PT1377164E/pt unknown
- 2002-04-08 BR BR0208727-8A patent/BR0208727A/pt not_active IP Right Cessation
- 2002-04-08 IL IL15815502A patent/IL158155A0/xx unknown
- 2002-04-08 JP JP2002578724A patent/JP4428924B2/ja not_active Expired - Fee Related
- 2002-04-08 RU RU2003132584/14A patent/RU2296563C2/ru not_active IP Right Cessation
- 2002-04-08 HU HU0303838A patent/HUP0303838A3/hu unknown
- 2002-04-08 CA CA002443025A patent/CA2443025A1/en not_active Abandoned
- 2002-04-08 AU AU2002256133A patent/AU2002256133B2/en not_active Ceased
- 2002-04-08 WO PCT/US2002/011081 patent/WO2002080676A1/en active Application Filing
- 2002-04-08 ES ES02725577T patent/ES2309166T3/es not_active Expired - Lifetime
2003
- 2003-09-29 IL IL158155A patent/IL158155A/en not_active IP Right Cessation
- 2003-10-06 ZA ZA200307803A patent/ZA200307803B/en unknown
- 2003-10-08 NO NO20034504A patent/NO20034504L/no not_active Application Discontinuation
2009
- 2009-05-17 IL IL198783A patent/IL198783A0/en unknown
2011
- 2011-03-31 US US13/077,335 patent/US20110195046A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2002080676A1 (en)	2002-10-17
IL198783A0 (en)	2010-02-17
CN101152565A (zh)	2008-04-02
BR0208727A (pt)	2005-05-10
KR20030087064A (ko)	2003-11-12
PT1377164E (pt)	2008-09-30
ATE399020T1 (de)	2008-07-15
CN100379446C (zh)	2008-04-09
RU2003132584A (ru)	2005-04-10
DK1377164T3 (da)	2008-10-13
JP2004532840A (ja)	2004-10-28
ES2309166T3 (es)	2008-12-16
NZ528675A (en)	2006-10-27
JP4428924B2 (ja)	2010-03-10
CN1499927A (zh)	2004-05-26
US20020169128A1 (en)	2002-11-14
NO20034504L (no)	2003-12-09
RU2296563C2 (ru)	2007-04-10
IL158155A0 (en)	2004-03-28
MXPA03009182A (es)	2004-02-17
CA2443025A1 (en)	2002-10-17
PL373361A1 (en)	2005-08-22
EP1377164A1 (en)	2004-01-07
EP1377164B1 (en)	2008-06-25
NO20034504D0 (no)	2003-10-08
IL158155A (en)	2009-12-24
US20110195046A1 (en)	2011-08-11
KR100885525B1 (ko)	2009-02-26
EP1377164A4 (en)	2005-05-04
HUP0303838A3 (en)	2010-03-29
AU2002256133B2 (en)	2007-05-31
DE60227244D1 (de)	2008-08-07
HUP0303838A2 (hu)	2004-03-01

Publication	Publication Date	Title
US20110195046A1 (en)	2011-08-11	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
AU2002256133A1 (en)	2003-04-10	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
ES2231889T3 (es)	2005-05-16	Procedimiento de tratamiento de lesiones endoteliales.
JP2009513682A (ja)	2009-04-02	相乗的効果を奏する割合でγ−及びα−インターフェロンを含有する安定化製剤
US20020052317A1 (en)	2002-05-02	Anti-viral and anti-tumor chemotherapy by administration of erythropoeitin
KR100519904B1 (ko)	2005-10-10	에리트로포이에틴 및 개질된 헤모글로빈을 함유하는 약학복합제제
JP7682303B2 (ja)	2025-05-23	進行固形腫瘍を治療する薬物の製造のためのミトキサントロン塩酸塩リポソームの用途
TWI725947B (zh)	2021-05-01	巴豆酯組成物及用於治療或減少血球細胞減少期間之用途
HUP0300560A2 (hu)	2003-06-28	Mobilizáló hatású készítmény
EP1930023A2 (en)	2008-06-11	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
TWI327473B (en)	2010-07-21	Composition for treating a cerebrovascular disease and a method for increasing expression of erythropoietin
US20060166885A1 (en)	2006-07-27	Treatment and prevention of decubitus
JPH06340549A (ja)	1994-12-13	ネコの呼吸器疾患治療剤とその治療剤を用いる治療方法
EP3570849B1 (en)	2024-12-25	Pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
JPH03190823A (ja)	1991-08-20	エリスロポエチン皮下又は筋肉投与剤
De Vries et al.	1993	Drug resistance, supportive care and dose intensity
WO1992011022A1 (en)	1992-07-09	Pharmaceutical preparation for pernasal administration
Goodnough	2020	10 Pharmacologic alternatives to
EP0731710B1 (en)	2003-05-14	Thymosine alpha 1 containing compositions for the treatment of patients having decompensated liver disease
Noël	2000	26 Hematopoietic Growth Factors
AU2005231307A1 (en)	2005-10-20	Combination dosing regimen for erythropoietin
NZ731599B2 (en)	2021-08-03	Phorbol ester compositions and methods for treating or reducing the duration of cytopenia
HK1021685B (en)	2004-03-19	Thymosine alpha 1 containing compositions for the treatment of patients having decompensated liver disease